Physician profile
Steven M Smith
NPI 1588617666
$623.86
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $367 · 2022: $187 · 2023: $70.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $107.87 | 2021-2022 | |
| Amgen INC. | $87.16 | 2021-2022 | |
| Novo Nordisk INC | $70.55 | 2023 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $69.46 | 2021-2022 | |
| Abbvie INC. | $58.76 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.42 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $44.16 | 2021-2022 | |
| Pfizer INC. | $25.50 | 2021 | |
| Amarin Pharma, INC. | $21.64 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $21.30 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.50 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.72 | 2021 | |
| Merck Sharp & Dohme LLC | $12.41 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.